Incyte causes stir with experimental drug data

Incyte made a stir at JP Morgan with positive early-stage results for its experimental drugs aimed at rheumatoid arthritis and diabetes. Its shares jumped about 25 percent on the news. Chief Executive Dr. Paul Friedman said early data from INCB18424 appear to show "at least equal, and possibly superior," results compared to other biologics, adding that the drug was well tolerated.

- read the release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.